🇺🇸 FDA
Pipeline program

Testosterone Transdermal System

2001134 and Yr 2-4 OL

Phase 3 small_molecule completed

Quick answer

Testosterone Transdermal System for Hypoactive Sexual Desire Disorder is a Phase 3 program (small_molecule) at Warner Chilcott Deutschland GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Warner Chilcott Deutschland GmbH
Indication
Hypoactive Sexual Desire Disorder
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials